Back to top
more

Pieris Pharmaceuticals (PIRS)

(Delayed Data from NSDQ)

$16.83 USD

16.83
6,141

+0.35 (2.12%)

Updated Nov 8, 2024 03:08 PM ET

After-Market: $16.72 -0.11 (-0.65%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of 10.66% and 74.38%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's Why

by Zacks Equity Research

Pieris Pharmaceuticals (PIRS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

Pieris Pharmaceuticals (PIRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

New Strong Buy Stocks for August 23rd

by Zacks Equity Research

JHX, CWCO, GPI, CEG and PIRS have been added to the Zacks Rank #1 (Strong Buy) List on August 23, 2023.

Merck's (MRK) Welireg Meets Renal Cell Carcinoma Study Goals

by Zacks Equity Research

Based on interim data from a late-stage study, Merck's (MRK) Welireg achieves statistically significant improvements in one of the study's dual endpoints of progression-free survival.

UroGen Pharma (URGN) Stock Surges 89% in a Month: Here's Why

by Zacks Equity Research

This jump in UroGen's (URGN) stock price is attributable to positive data from two late-stage studies on bladder cancer therapy. An FDA filing for the candidate is expected next year.

Pieris (PIRS) Up On Receiving Milestone Payment From Partner

by Zacks Equity Research

Pieris (PIRS) soars as partner Boston Pharmaceuticals initiated early-stage study of PRS-342/BOS-342, triggering an undisclosed milestone payment to the former.

Alaunos (TCRT) to Wind Down Sole Clinical Study, Stock Dips 65%

by Zacks Equity Research

Due to a lack of funding needs, Alaunos (TCRT) decides to end its only clinical study. The company will instead focus on its hunTR TCR discovery platform and explore broad strategic alternatives.

New Strong Buy Stocks for August 16th

by Zacks Equity Research

GM, IBN, PIRS, GPI and MBWM have been added to the Zacks Rank #1 (Strong Buy) List on August 16, 2023.

ChromaDex (CDXC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

ChromaDex (CDXC) delivered earnings and revenue surprises of 25% and 4.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Pieris (PIRS) Pursues Strategic Alternatives, Stock Rises

by Zacks Equity Research

Pieris (PIRS) announces strategic update after partner AstraZeneca terminated collaboration agreement and returned the rights to elarekibep.

Pieris (PIRS) Declines as AZN Halts Study of Asthma Candidate

by Zacks Equity Research

Pieris' (PIRS) shares nosedive as its partner decides to discontinue a phase IIa study evaluating elarekibep for treating asthma, based on non-clinical safety data from a toxicology study.

Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of -28.57% and 70.24%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -16.67% and 6.76%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Pieris Pharmaceuticals (PIRS) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 15.38% and 10.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Acadia Healthcare (ACHC) Misses Q4 Earnings Estimates

by Zacks Equity Research

Acadia Healthcare (ACHC) delivered earnings and revenue surprises of -5.41% and 2.45%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Immunocore Holdings PLC Sponsored ADR (IMCR) Surges 6.5%: Is This an Indication of Further Gains?

by Zacks Equity Research

Immunocore Holdings PLC Sponsored ADR (IMCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Pieris Pharmaceuticals (PIRS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 18.75% and 19.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Pieris Pharmaceuticals (PIRS) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of -27.27% and 64.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Pieris Pharmaceuticals (PIRS) Loses 41.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Pieris Pharmaceuticals (PIRS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

After Plunging 45.5% in 4 Weeks, Here's Why the Trend Might Reverse for Pieris Pharmaceuticals (PIRS)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Pieris Pharmaceuticals (PIRS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 41.67% and 2.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Pieris Pharmaceuticals (PIRS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 56.67% and 71.96%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Heska (HSKA) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Heska (HSKA) delivered earnings and revenue surprises of 9.38% and 3.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Do Options Traders Know Something About Pieris Pharmaceuticals (PIRS) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to for Pieris Pharmaceuticals (PIRS) stock based on the movements in the options market lately.